GlassScriptPhysician profile
Robert M Foster
NPI 1417991613
$1,894.55
in general payments reported to CMS, 2019-2025
30 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $128 · 2021: $60.30 · 2022: $298 · 2023: $509 · 2024: $372 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $307.56 | 2019-2025 | Wegovy, Ozempic |
| Collegium Pharmaceutical, INC. | $211.02 | 2020-2025 | Belbuca, Xtampza |
| Abbvie INC. | $152.96 | 2022-2024 | |
| Genentech, INC. | $150.00 | 2024 | Vabysmo |
| Pfizer INC. | $96.69 | 2021-2025 | |
| Amgen INC. | $94.00 | 2022-2024 | Otezla, Repatha |
| Lilly USA, LLC | $92.02 | 2020-2023 | Mounjaro |
| Forte Bio-Pharma LLC | $74.36 | 2019-2024 | Prolate, Nalocet |
| Horizon Therapeutics Plc | $73.65 | 2022 | |
| Masimo Corporation | $73.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $63.93 | 2019 | |
| Indivior INC. | $54.42 | 2024 | Sublocade |
| Supernus Pharmaceuticals, INC. | $53.31 | 2020-2023 | Qelbree |
| Glaxosmithkline, LLC. | $49.12 | 2023 | Trelegy Ellipta |
| Genentech USA, INC. | $43.19 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $36.04 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.33 | 2019-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $25.72 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $22.03 | 2023 | Rexulti |
| Philips North America LLC | $19.80 | 2023 | |
| Neurocrine Biosciences, INC. | $19.18 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.52 | 2019 | |
| Valinor Pharma, LLC | $16.38 | 2025 | Movantik |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.88 | 2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $14.91 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.21 | 2023 | Linzess |
| Exact Sciences Corporation | $14.04 | 2023 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $13.56 | 2019 | |
| Currax Pharmaceuticals LLC | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.